Muting lives news
Personalised Cancer Medicine in Phase 1 Cancer Research at Rigshospitalet Ulrik Lassen MD, PH.D Phase 1 Unit.
ALK and Other Evolving Targets in Advanced NSCLC Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division.
UNIVERSITY OF TORINO – DEPARTMENT OF ONCOLOGY Treatment of ALK- and ROS-1 translocated NSCLC Massimo Di Maio, MD Department of Oncology, University of.
Stem Cells In Clinical Practice: STELLA Experience Manolo D’Arcangelo Department of Oncology Ospedale Civile di Livorno.
Personalised Cancer Medicine in Phase 1 Cancer Research at Rigshospitalet
EML4-ALK: Oncogene Addiction Meets Personalized Medicine Thomas J Lynch, MD Jonathan and Richard Sackler Professor of Internal Medicine Director, Yale.
